Imagene AI (Nasdaq: IMA), a Miami-based precision oncology AI company, announced a collaboration with Japan-based Daiichi Sankyo (TSE: 4568) to apply Imagene’s OI Suite platform to biomarker discovery and response prediction in support of select antibody-drug conjugate (ADC) development programs. Financial terms and specific assets were not disclosed.
Under the agreement, Daiichi Sankyo will use Imagene’s platform — built on its CanvOI foundation model — to analyze H&E (hematoxylin and eosin staining) and IHC (immunohistochemistry) whole-slide images alongside molecular and clinical datasets. The aim is to improve patient stratification and inform biomarker hypotheses earlier in development.
A core focus is Imagene’s “Composite Continuous Scoring” approach to IHC, a technique that uses antibodies to detect and quantify protein expression in tissue samples. Inmagene’s system replaces traditional categorical scoring (0-3+) with a continuous readout of target expression. This reflects a growing need in ADC development for more precise quantification, particularly as therapies expand into lower or heterogeneous expression populations.